The magnitude of delay in non-metastatic breast cancer treatment in a tertiary hospital: An analysis from 2012 to 2018
https://doi.org/10.47895/amp.vi0.9028
- Author:
Rogelio N. Velasco, Jr.
1
;
Mark M. Ando
1
;
Mark Anthony U. Javelosa
2
;
Rich Ericson C. King
1
;
Karen Anjela M. Mondragon
1
;
Harold Nathan C. Tan
1
;
Corazon A. Ngelangel
1
;
Irisyl O. Real
1
Author Information
1. Division of Medical Oncology, Department of Medicine, Philippine General Hospital, University of the Philippines Manila
2. Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila
- Publication Type:Journal Article
- MeSH:
breast cancer;
quality of care;
treatment delays
- From:
Acta Medica Philippina
2024;58(Early Access 2024):1-7
- CountryPhilippines
- Language:English
-
Abstract:
Background and Objective:The burden of treatment delay in breast cancer is high, especially among developing countries. Despite adversely affecting morbidity and mortality, treatment delay remains unexplored in the Philippines. This study aimed to determine treatment delays among breast cancer patients in a tertiary hospital during surgery, neoadjuvant chemotherapy, and adjuvant chemotherapy, and to identify predictors of delay.
Methods:A cross-sectional study was conducted among breast cancer patients seen between January 1, 2012 to December 31, 2018. The following outcomes were investigated: ≥90 days from initial diagnosis to surgery, ≥8 weeks from diagnosis to initiation of neoadjuvant chemotherapy, and >120 days from diagnosis to initiation of adjuvant chemotherapy. Summary statistics were reported as percent for categorical data and as mean for continuous data. The individual correlations were performed using Chi-square for qualitative data and t-test for quantitative data while predictors were determined through logistic regression.
Results:A total of 324 patients were included in this study. The majority of the patients were less than 65 years old living in urban areas. More than half of the patients were overweight or obese, hypertensive, and diabetic. The following delays were observed: 61.1% (n = 198) with any type of delay, 23.8% (n = 53) with delay in surgery, 53.8% (n = 120) with delay in adjuvant chemotherapy, and 74.3% (n = 75) with delay in neoadjuvant chemotherapy. The patients noted to have any type of delay were more likely to be hypertensive (p = 0.046) and residing in urban areas (p = 0.041). There were no differences in the distribution of age, body mass index, and presence of co-morbid conditions such as hypertension, diabetes mellitus, coronary artery disease, and heart failure among those with any form of delay compared with no delay.
Conclusions:The present study shows the presence of treatment delay among breast cancer patients and may be used to enact policy changes to optimize breast cancer care delivery. Further studies may be done to identify other factors affecting these delays and policy changes are recommended to address these gaps in surgery and chemotherapy administration among breast cancer patients.
- Full text:20240905174618078798.pdf
